Here’s some gut-wrenching news. A troubling complication of colorectal cancer, the third-most common cancer in the US, is ...

Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...

Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

Incyte ($INCY) announced an update on their ongoing clinical study. Study Overview Incyte’s new Phase 3 trial, titled “A Randomized, Double-Blind, ...

Patients with prior malignancy showed improved cancer-specific survival in metastatic colorectal cancer (mCRC), but prior skin tumors or malignancies diagnosed over five years earlier worsened ...

The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...

"The presence of tumor deposits indicates a higher risk of cancer recurrence at every stage...We should update our tumor staging protocols to include tumor deposits even when lymph node metastases are ...

mCRC treatment involves balancing efficacy, tolerability, and patient goals, with fruquintinib, regorafenib, and trifluridine-tipiracil as key therapies. Oncology pharmacists are essential in ...

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by ...